INTRODUCTION AND AIM: Calcineurin inhibitor (CNI) dose reduction or late withdrawal may be ineffective for chronic kidney disease (CKD) prevention once it has developed after liver transplantation (LT). We carried out a 2:1 ratio randomized trial to assess whether early withdrawal of CNI followed by initiation of everolimus (Evr) monotherapy in de novo liver transplant would lead to superior renal function compared to a cyclosporine (CsA) based immunosuppression protocol. PATIENTS AND METHODS: All patients were treated with CsA for the first 10 days, then they were randomized to receive Evr in combination with CsA up to day 30, then continued on Evr as monotherapy (Evr Group) or to maintain CsA with/without mycophenolate mofetil in case of CKD (CsA Group). All patients received a basiliximab induction on day 0 and 5 after LT and were tapered off steroids by 5 weeks. Fifty-one consecutive patients were enrolled (Evr n=34; CsA n=17), all of them reached a post-LT follow-up equal or longer than 12 months. All main patient characteristics resulted similar between the two groups in terms of demographics, MELD score and LT indication. RESULTS: There was no statistically significant difference in 1-year patient survival that was 82.4% and 85.3% in CsA and Evr Group respectively. Mean estimated glomerular filtration rate (eGFR), calculated with MDRD formula, was similar in the two groups at randomization, but was significantly better in the Evr Group at 6 months (86.5±36.4 vs. 51.2±13.9 mL/min/1.73m2; p=0.002) and at 12 months (85.6±24.3 vs. 59.8±12 mL/min/1.73m2;p=0.001). At the end of follow-up 9 patients out of 17 (52.9%) in CsA Group and 7 out of 34 (20.6%) in Evr Group experienced a stage ≥3 CKD (eGFR<60 mL/min/1.73m2; p=0.043). The incidence of rejection episodes, major infections, HCV recurrence and triglycerides and cholesterol mean levels were similar in the two groups (p=NS). Incisional hernia in Evr Group occurred in 44.1% vs. 17.6% of patients in CsA Group, although the difference was not statistically significant (p=0.12). The incidence of neurological complications resulted significantly higher in CsA Group (17.6 vs. 0%, p=0.03). CONCLUSIONS: Early withdrawal of CsA followed by Evr monotherapy in de novo LT is associated with a statistically significant improvement in 6- and 12-months renal function with a lower incidence of neurological complications and a similar incidence of rejection episodes and other major complications.

Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients / Montalti, R; Masetti, M; Rompianesi, G; Serra, V; Di Benedetto, F; De Ruvo, N; Cautero, N; Ballarin, R; Iemmolo, Rm; Guerrini, Gp; Gerunda, Ge. - (2009). (Intervento presentato al convegno International Liver Transplantation Society (ILTS) 15th Annual International Congress tenutosi a New York, NY. nel July 08 - 11, 2009).

Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients

Montalti R
;
Rompianesi G;
2009

Abstract

INTRODUCTION AND AIM: Calcineurin inhibitor (CNI) dose reduction or late withdrawal may be ineffective for chronic kidney disease (CKD) prevention once it has developed after liver transplantation (LT). We carried out a 2:1 ratio randomized trial to assess whether early withdrawal of CNI followed by initiation of everolimus (Evr) monotherapy in de novo liver transplant would lead to superior renal function compared to a cyclosporine (CsA) based immunosuppression protocol. PATIENTS AND METHODS: All patients were treated with CsA for the first 10 days, then they were randomized to receive Evr in combination with CsA up to day 30, then continued on Evr as monotherapy (Evr Group) or to maintain CsA with/without mycophenolate mofetil in case of CKD (CsA Group). All patients received a basiliximab induction on day 0 and 5 after LT and were tapered off steroids by 5 weeks. Fifty-one consecutive patients were enrolled (Evr n=34; CsA n=17), all of them reached a post-LT follow-up equal or longer than 12 months. All main patient characteristics resulted similar between the two groups in terms of demographics, MELD score and LT indication. RESULTS: There was no statistically significant difference in 1-year patient survival that was 82.4% and 85.3% in CsA and Evr Group respectively. Mean estimated glomerular filtration rate (eGFR), calculated with MDRD formula, was similar in the two groups at randomization, but was significantly better in the Evr Group at 6 months (86.5±36.4 vs. 51.2±13.9 mL/min/1.73m2; p=0.002) and at 12 months (85.6±24.3 vs. 59.8±12 mL/min/1.73m2;p=0.001). At the end of follow-up 9 patients out of 17 (52.9%) in CsA Group and 7 out of 34 (20.6%) in Evr Group experienced a stage ≥3 CKD (eGFR<60 mL/min/1.73m2; p=0.043). The incidence of rejection episodes, major infections, HCV recurrence and triglycerides and cholesterol mean levels were similar in the two groups (p=NS). Incisional hernia in Evr Group occurred in 44.1% vs. 17.6% of patients in CsA Group, although the difference was not statistically significant (p=0.12). The incidence of neurological complications resulted significantly higher in CsA Group (17.6 vs. 0%, p=0.03). CONCLUSIONS: Early withdrawal of CsA followed by Evr monotherapy in de novo LT is associated with a statistically significant improvement in 6- and 12-months renal function with a lower incidence of neurological complications and a similar incidence of rejection episodes and other major complications.
2009
Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients / Montalti, R; Masetti, M; Rompianesi, G; Serra, V; Di Benedetto, F; De Ruvo, N; Cautero, N; Ballarin, R; Iemmolo, Rm; Guerrini, Gp; Gerunda, Ge. - (2009). (Intervento presentato al convegno International Liver Transplantation Society (ILTS) 15th Annual International Congress tenutosi a New York, NY. nel July 08 - 11, 2009).
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/759585
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact